Microbot Medical appoints former Olympian as VP of sales

HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), whose stock has surged over 130% in the past year, has appointed Christina Bailey as its new Vice President of Sales, according to a company press release issued Tuesday.

Bailey, a two-time U.S. Olympian with 20 years of medical device sales experience, will report directly to Harel Gadot, the company’s CEO, President and Chairman.

The new sales executive previously held leadership positions at several major medical device companies including Boston Scientific, Abbott, Stryker and Intuitive Surgical. Most recently, she served as Vice President of US Sales at Endologix, where she built and scaled the sales team.

Bailey is also known for her athletic achievements as a member of the U.S.A. Women’s Hockey Team, winning a gold medal at the 1998 Winter Olympics in Nagano, Japan. She currently serves as a Board Member for USA Hockey.

Microbot Medical is developing the LIBERTY Endovascular Robotic System, which the company describes as the world’s first single-use, fully disposable endovascular robotic system. The device is currently under FDA review, pending 510(k) clearance, and is not yet available for sale in the United States.

The company states Bailey will focus on establishing a sales team to support the anticipated launch of the LIBERTY system.

Microbot Medical is a pre-commercial stage medical technology company based in Massachusetts that aims to redefine endovascular robotics.

In other recent news, Microbot Medical Inc. has raised $3 million through the exercise of Series F and Series G preferred investment options. The company issued 1,808,336 shares of common stock, with Series G options exercised at $1.75 per share, generating approximately $1.8 million, and Series F options exercised at $1.50 per share, bringing in about $1.175 million. Additionally, Microbot Medical has been granted a patent in China for robotic manipulation of surgical tool handles, expanding its intellectual property portfolio to nine granted patents globally. Following a recent stockholder vote, the company increased its authorized common stock from 60 million to 120 million shares. Analysts at H.C. Wainwright reiterated a Buy rating with a $9.00 price target for Microbot Medical, citing the upcoming potential U.S. launch of its LIBERTY endovascular robotic system. The company is preparing for this anticipated launch in the third quarter of 2025, pending FDA review of its 510(k) premarket notification. As part of its preparations, Microbot Medical has appointed Michael Lytle as head of Sales Operations & Analytics to strengthen its commercial team. These developments reflect the company’s strategic efforts to enhance its market presence and technological capabilities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.